Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Continuity-Bioscience

More Like This

Fast Company Magazine has honored Xenco Medical for its groundbreaking TrabeculeX Continuum technology with its 2024 Innovation by Design Award. (Photo: Business Wire)

Fast Company Magazine Awards Xenco Medical with 2024 Innovation by Design Award for the TrabeculeX Continuum

PR Newswire associated0

Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform

PartitionBio™ awarded grant to exploit its novel biologics shuttle platform for therapeutic nucleic acids delivery

On January 11th, trailblazing medical technology company Xenco Medical unveiled its convergent technology bridging Digital Health and Biomaterials by showcasing its TrabeculeX Continuum™ at the 2024 Consumer Electronics Show in Las Vegas, Nevada. Comprising the TrabeculeX Bioactive Matrix™ and the TrabeculeX Recovery App™, the TrabeculeX Continuum is the first technology-enabled bridge between orthobiologics and digital health, unifying a patient’s biomaterial implantation and postoperative journey. (Graphic: Business Wire)

Xenco Medical Unveils the TrabeculeX Continuum, a Breakthrough Convergence of Digital Health and Biomaterials, at CES 2024 in Las Vegas, the World’s Largest Technology Conference

Biotech Award presented to Paul Bravetti (CEO Brenus Pharma) by Thierry Hulot (President of Merck Group activities in France - President of LEEM), Alain Huriez (Chariman and Managing Partner, AdBio Partners), Guillaume LAULHE (Director BD at IQVIA) (Photo: Brenus Pharma)

Brenus Pharma Wins the "Biotech" Trophy at the Prestigious Healthtech 2024 Awards Ceremony, Organized by France Biotech

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical Trial Preparations, Signaling Major Shift to Clinical Stage with DKK40M Financing Secured

Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation